23andMe and 20 lung cancer advocacy organizations are working to improve lung cancer detection, risk reduction and care. 23andMe, the genetic health and biopharmaceutical company, has partnered with ...
The Lung Cancer Genetics Study, a collaboration between lung cancer advocacy organizations, aims to explore the genetics of lung cancer Imagine being diagnosed with the same disease that took away ...
5don MSN
Major gaps block genetic evaluation and testing for Black and low income patients, study finds
Black patients and patients from socioeconomically disadvantaged neighborhoods are dramatically under-represented in genetics clinics—often at rates half or less than those of white patients or ...
Myriad Genetics, Inc. announced a study indicating that the use of its online screening tool, MyGeneHistory®, alongside a virtual education program, significantly increased the completion rates for ...
Opus Genetics, Inc. ((IRD)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...
Study finds significantly lower rates of provider-initiated exome reanalysis among diverse racial, ethnic, and ancestral groups highlighting the importance of proactive reanalysis offerings like Ambry ...
Myriad Genetics, Inc. announced that a study published in the Journal of Clinical Psychopharmacology found that the GeneSight® Psychotropic Test significantly reduced psychiatric hospitalizations in ...
Peer-reviewed publication examines the benefits of proactive exome reanalysis on diagnostic outcomes Ambry Genetics’ Patient for Life program is supported by a dedicated team of scientists who ...
Anil Oza is a general assignment reporter at STAT focused on the NIH and health equity. You can reach him on Signal at aniloza.16. A large government study published Thursday shows more definitively ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback